By Sonya Colberg, TheStreetSweeper Senior Investigative Reporter Tekmira Pharmaceuticals (NASDAQ:TKMR) may not have found its next big biotech thing, after all. After a …
Well, one IPO we were eagerly awaiting is no longer on this year’s docket with Tekmira’s (NASDAQ:TKMR) merger agreement with Oncore announced tonight …
In a research note released August 14, Maxim Group analyst Jason Kolbert maintained a Buy rating on Tekmira Pharmaceuticals (TKMR) with a $23 price target, following the company’s second-quarter results. Tekmira ended the quarter …
In a research note issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Tekmira Pharmaceuticals (TKMR) with a $23 price target, following a report that created a buzz around Ebola drug …
